Abstract 999P
Background
Both donafenib and anti-PD-1 antibodies are indicated for uHCC, HAIC significantly improved treatment response over TACE in patients (pts) with large uHCC in a phase III trial. Considering the different mechanisms, this study aimed to investigate the safety and efficacy of donafenib combined with HAIC and sintilimab in pts with uHCC.
Methods
This is a prospective, single-arm phase II study. Pts with histologically diagnosed uHCC, no previous systemic treatment, Child-Pugh A5-B7, ECOG performance status (PS) of 0 or 1 were eligible for inclusion. Enrolled pts received donafenib (200 mg, bid), sintilimab (200 mg, q3w) and HAIC (oxaliplatin 85 mg/m2 2h, leucovorin 400 mg/m2 2h, fluorouracil bolus 400 mg/m2 in the first 10 minutes, and fluorouracil infusion 1200 mg/m2 for 23 hours, q3w) until disease progression or unacceptable toxicity. The primary endpoint was objective response rate (ORR).
Results
From Dec 2021 to Apr 2023, 30 pts were enrolled: BCLC stage A/B/C: 4/10/16; Child-Pugh class A/B: 29/1; ECOG PS 0/1: 29/1. The median tumor size was 7.9 cm, 46.7% pts presented macro vascular invasion, 10.0% had extrahepatic metastasis. As of May 6, 2023, the median follow-up time was 102 days, the median number of HAIC was 3 times (range, 1-8). Based on mRECIST, the ORR was 82.1% (95% CI, 63.1% - 93.9%) with 4 (14.3%) complete responses (CR) and 19 (67.8%) partial responses (PR). The disease control rate (DCR) was 96.4% (95% CI, 81.7% - 99.9%). Of 28 pts evaluable for response, the conversion success rate was 64.3% (18/28), 13 of them received hepatectomy, 5 cases (38.5%) achieved complete pathological response and 6 cases (46.2%) achieved major pathological response. The median time to response (TTR) was 2.1 months. The median progression-free survival (PFS) was 10.2 months (95% CI, NR). The most common treatment-emergent adverse events (TEAEs) were thrombocytopenia, anemia and neutropenia. Grade 3-4 TEAEs occurred in 33.3% of pts. No grade 5 TEAEs were observed.
Conclusions
Combination treatment with donafenib and HAIC plus sintilimab showed promising clinical benefits and acceptable toxic effects in pts with uHCC. The enrollment and follow-up are continuing.
Clinical trial identification
NCT05166772.
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
946P - Sintilimab plus lenvatinib as conversion therapy in patients with unresectable hepatocellular carcinoma: A prospective, non-randomized, open-label, phase II, expansion cohort study
Presenter: Shichun Lu
Session: Poster session 18
947P - The efficacy and safety of cadonilimab combined with lenvatinib for first-line treatment of advanced hepatocellular carcinoma: A phase Ib/II clinical trial
Presenter: Li Bai
Session: Poster session 18
949P - Regorafenib combined with immunotherapy versus regorafenib as second-line therapy in patients with advanced hepatocellular carcinoma: A multicenter real-world study
Presenter: Bin-Kui Li
Session: Poster session 18
952P - Efficacy and safety of a PRospective, Observational trial of Lenvatinib cOmbined with transarterial chemoembolization (TACE) as initial treatment for advaNced staGe hepatocellular carcinoma (PROLONG): A multicenter, single-armed, real-world study
Presenter: Guoliang Shao
Session: Poster session 18
953P - Tislelizumab plus regorafenib as second-line therapy for unresectable hepatocellular carcinoma (uHCC): A single-arm, phase II trial
Presenter: Zhongchao Li
Session: Poster session 18
954P - Radiotherapy combined with tislelizumab plus anlotinib as first-line treatment for hepatocellular carcinoma: A single arm, phase II clinical trial
Presenter: Guishu wu
Session: Poster session 18
955P - IMMUNIB trial (AIO-HEP-0218/ass): A single-arm phase II study evaluating safety and efficacy of immunotherapy with nivolumab in combination with lenvatinib in advanced hepatocellular carcinoma
Presenter: Arndt Vogel
Session: Poster session 18